Equity strategies

Carmignac Portfolio Grandchildren

Global marketArticle 9
Share Class

LU2420652476

An intergenerational Fund focused on quality, sustainable companies
  • A Fund focused on selecting high-quality companies around the world, with sound financials and sustainable profitability.
  • An investment process based on rigorous fundamental analysis, quantitative screening, and a socially responsible investment approach.
  • A concentrated, low turnover portfolio of high-conviction names seeking to provide steady growth of your capital over the long term.
Key documents
Asset Allocation
Equities95.4 %
Other4.6 %
Data as of:  Oct 31, 2025.
Risk Indicator

1

2

3

4

5

6

7

Lowest risk Highest risk
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
+ 10.3 %
-
-
+ 35.8 %
- 8.0 %
From 31/12/2021
To 04/12/2025
Calendar Year Performance 2024
-
-
-
-
-
-
-
- 23.7 %
+ 23.8 %
+ 22.7 %
Net Asset Value
110.26 €
Asset Under Management
415 M €
Net Equity Exposure31/10/2025
95.4 %
SFDR - Fund Classification

Article

9
Data as of:  Dec 4, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.

Carmignac Portfolio Grandchildren fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  Nov 28, 2025.
Fund management team
[Management Team] [Author] Denham Mark

Mark DENHAM

Head of Equities, Fund Manager
[Management Team] [Author] Ejikeme Obe

Obe EJIKEME

Fund Manager, Analyst

Market environment

  • Equity markets were broadly unchanged in November, but performance varied significantly beneath the surface.
  • Growth stocks, despite solid fundamentals, struggled to lead, while traditionally defensive areas like healthcare and consumer staples saw a clear rebound.
  • The end of the U.S. government shutdown did little to boost sentiment, as investors remained cautious amid mixed economic signals, questions around the growth outlook, and uncertainty on the direction of monetary policy.
  • Q3 earnings season ended on a strong note. In the U.S., 81% of S&P 500 companies beat expectations, with earnings up 13% year-on-year. Tech results were particularly strong, but the market didn’t react, suggesting that expectations are already high.
  • In Europe, financials and technology continued to deliver solid results, while consumer sectors, especially autos, were weaker. European equities slightly outperformed, supported by robust earnings growth prospects for 2026.
  • Elsewhere in Asia, markets softened as investors took profits after a strong year, with Korea and Taiwan retreating following a pullback in AI-related names.

Performance commentary

  • In November, the Fund delivered a negative absolute and relative performance.
  • The relative underperformance was mainly driven by the technology sector as November marked the sharpest tech-led correction since April.
  • This downturn was driven by elevated valuations and bubble concerns, compounded by fading expectations for Fed rate cuts mid-month.
  • Strong compounders such as Microsoft and ServiceNow were also caught in the selloff, penalized by macro-driven sentiment and AI-related execution concerns, despite solid fundamentals and strong prior performance.
  • Conversely, after several months of softness, our healthcare holdings delivered strong absolute returns. Eli Lilly led the way, surging about 25% on the back of robust EPS and revenue growth.
  • Similarly, our consumer staples positions, including Colgate and L’Oréal, posted solid gains, highlighting their resilience amid market volatility.

Outlook strategy

  • Our macroeconomic framework continues to advocate a defensive positioning, as valuation remains a key concern at the overall market level.
  • During the month, we made several portfolio adjustments fully exiting our positions in Danaher and Eli Lilly following their strong performance.
  • We initiated new positions in Arista Networks and Doximity after recent weakness, as both companies demonstrate solid growth prospects and robust balance sheets.
  • Defensive sectors are trading at their most attractive relative valuations in nearly two decades, offering resilience and diversification benefits should growth expectations disappoint.
  • In the current environment, earnings visibility is likely to be increasingly rewarded. We therefore maintain a disciplined stance, limiting exposure to cyclical sectors in favour of quality.
  • Our portfolio remains positioned to benefit from secular growth trends such as AI and digital transformation, while maintaining the flexibility and discipline needed to navigate an uncertain macro backdrop.

Performance Overview

Data as of:  Dec 4, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
Source: Carmignac at 07/12/2025

Carmignac Portfolio Grandchildren Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  Oct 31, 2025.
North America62.7 %
Europe37.3 %
View details

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  Oct 31, 2025.
Equity Investment Weight95.4 %
Net Equity Exposure95.4 %
Number of Equity Issuers41
Active Share78.0 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Managers.
Fund Management Team
[Management Team] [Author] Denham Mark

Mark DENHAM

Head of Equities, Fund Manager
[Management Team] [Author] Ejikeme Obe

Obe EJIKEME

Fund Manager, Analyst
Carmignac Portfolio Grandchildren is an intergenerational Fund that focuses on high-quality companies to help investors build capital not only for themselves, but also for future generations.
[Management Team] [Author] Denham Mark

Mark DENHAM

Head of Equities, Fund Manager
View Fund's characteristics

Articles that may interest you

Strategies insightsOctober 16, 2025English

Carmignac Portfolio Grandchildren: Letter from the Fund Managers - Q3 2025

3 minute(s) read
Find out more
Strategies insightsJuly 14, 2025English

Carmignac Portfolio Grandchildren: Letter from the Fund Managers - Q2 2025

3 minute(s) read
Find out more
Strategies insightsApril 16, 2025English

Quality: your compass in an uncertain world

Find out more
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
​The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.